Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
Emilia QuattrocchiMikkel ØstergaardPeter C TaylorRonald F van VollenhovenMyron ChuStephen MallettHayley PerryRegina KurraschPublished in: PloS one (2016)
ClinicalTrials.gov 110635 ClinicalTrials.gov 110634 ClinicalTrials.gov 111752.
Keyphrases
- monoclonal antibody
- clinical trial
- open label
- rheumatoid arthritis
- endothelial cells
- phase ii
- high dose
- phase iii
- induced pluripotent stem cells
- squamous cell carcinoma
- phase ii study
- low dose
- radiation therapy
- interstitial lung disease
- double blind
- idiopathic pulmonary fibrosis
- systemic lupus erythematosus
- smoking cessation
- locally advanced